Pulmonary candidiasis
Methodology & AI Transparency ⓘ
Pulmonary candidiasis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code B37.1 in Infections & Antivirals, Pulmonary candidiasis requires antimicrobial stewardship (narrow-spectrum in Pulmonary candidiasis (B37.1: pathogen-directed duration) or) so specialists can calibrate treatment intensity against Complete Blood Count in Pulmonary candidiasis (B37.1: (WBC & Differential)) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Pulmonary candidiasis uses ICD-10 B37.1 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Workup highlights for Pulmonary candidiasis (B37.1): antimicrobial stewardship (narrow-spectrum in Pulmonary candidiasis (B37.1: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Objective lab/clinical target for Pulmonary candidiasis: Complete Blood Count in Pulmonary candidiasis (B37.1: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B37.1)) and C-Reactive Protein / in Pulmonary candidiasis (B37.1: Procalcitonin).
Ask our AI Specialists anything about Pulmonary candidiasis
What Is Pulmonary candidiasis?
Cataloged under federal diagnostic code B37.1 in Infections & Antivirals, Pulmonary candidiasis requires antimicrobial stewardship (narrow-spectrum in Pulmonary candidiasis (B37.1: pathogen-directed duration) or) so specialists can calibrate treatment intensity against Complete Blood Count in Pulmonary candidiasis (B37.1: (WBC & Differential)) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in infections & antivirals, Pulmonary candidiasis (B37.1) involves tissue neutrophil/lymphocyte recruitment [Pulmonary candidiasis B37.1]. progression correlates with shifts in Complete Blood Count in Pulmonary candidiasis (B37.1: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B37.1)).
Common Symptoms & Clinical Signs
- • Presentation of Pulmonary candidiasis (B37.1): regional lymph node in Pulmonary candidiasis (B37.1: tenderness or acute)
- • Secondary Pulmonary candidiasis clinical sign: acute fever, chills, in Pulmonary candidiasis (B37.1: malaise, and myalgias)
- • Symptom flares in Pulmonary candidiasis correlating with Complete Blood Count in Pulmonary candidiasis (B37.1: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (B37.1)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Pulmonary candidiasis (B37.1: pathogen-directed duration) or) evaluation (B37.1)
Pulmonary candidiasis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: Complete Blood Count in Pulmonary candidiasis (B37.1: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Pulmonary candidiasis (B37.1: Procalcitonin) | Resolution to baseline (B37.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Pulmonary candidiasis (B37.1: Culture & Sensitivity) | Pathogen clearance / negative test (B37.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pulmonary candidiasis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Clotrimazole DR Sheffield Athletes Foot, Forticept Antifungal Foot Gel • RxCUI 309367 | Azole Antifungal | 84% | $0.5112 | $ 6.49 /mo |
| Miconazole Oravig, Antifungal • RxCUI 998548 | Azole Antifungal | 93% | $0.4152 | $ 9.40 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pulmonary candidiasis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| New Insights on Relationship Between Time From Diagnosis and Morbidity/Mortality in lung Arterial: What a 1,156-Participant Study Found In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. Chest • 2021-07-15 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 33545163 ↗ |
| New Insights on Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic: What a 975-Participant Study Found Ensifentrine produced clinically meaningful improvements in multiple dyspnea measures in patients with symptomatic, moderate-to-severe COPD. Expert review of respiratory medicine • 2024-08-15 • Phase III Randomized Trial | N = 975 | 93/100 | PMID 39106052 ↗ |
| New Insights on Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based: What a 510-Participant Study Found Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating H. Chinese medical journal • 2025-11-20 • Phase III Randomized Trial | N = 510 | 93/100 | PMID 39965795 ↗ |
| What the Latest Evidence Really Says About Vasodilators for persistent lung high blood pressure of the newborn: A network Milrinone, Sildenafil, and Sildenafil_Milrinone reduced the mortality of neonates with PPHN. Pediatric pulmonology • 2024-12-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 39193897 ↗ |
Pulmonary candidiasis Patient Community & “People Like Me” Threads
Filter Pulmonary candidiasis community threads and patient logs by age, biological sex, dosage, and treatment duration.